Does QSC issue lot-specific documentation, or a batch certificate?

The lot number on the vial matches the certificate, which at least rules out the easy problem.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

What can I legitimately conclude from this figure?

Specifically, the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Stated carefully, if the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 25 Jul 2025 by tobias_maartens — updated for the 2026 guidance change

Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

It helps to be literal here: batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

More usefully, a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.